The Glasgow conference provides free access to presentations at the meeting with webcasts of all oral presentations.
A selection of these are included below.
Immunology of HIV persistence: implications for the development of a cure
Steve Deeks, University of California, San Francisco
A comprehensive and positive overview of strategies for cure research, concluding that although combination approaches are likely to be needed, that larger strategy studies should be running in patients within the next five years.
Where next for ARVs?
Roy Gulick, Weill Cornell Medicine, New York
A useful and comprehensive review tracking the continued improvements with latest ARVs and an overview of pipeline HIV compounds likely to overcome drug resistance to current drugs (including doravirine, bictegravir and GSK934/BMS-068, EFdA).
The talk also covers strategies using reduced drugs and dosing, new ways to deliver drugs, cost and access.
HIV treatment as prevention: from a research hypothesis to a new global target and beyond
Julio Montaner, British Columbia Centre for Excellence in HIV/AIDS, Vancouver
A historical perspective on the effectiveness and cost effectiveness of treatment as Prevention (TasP) as an essential cornerstone for overcoming the global HIV epidemic, well past the 90:90:90 targets, by one of the earliest proponents.
Initiation of ART early in HIV infection: START to finish
Jens D Lundgren, University of Copenhagen
An overview of the results of the START study – from first planning stages ten years ago to the numerous sub-studies and additional research since the main results were presented last year. Not only were the advantages of earlier treatment seen consistently across demographic and HIV subgroups.
More than a dozen recent analysis:
- Converting relative risk into absolute risks, showing numbers needed to treat by different subgroups,
- The greater prognostic use of CD4:CD8 ratio over CD4 count at higher CD4 counts, and
- Improved quality of life with earlier treatment.
- Plus unexpected finding that despite reduced inflammation from earlier ART this did not directly improve cardiovascular risk, cognitive function or pulmonary function.
Transition to adult care
Pablo Rojo, Complutense University, Madrid
An overview of the complexities of issues relating to both paediatric and adolescent care in relation to calendar year of infection and the implications this has for transitioning to adult care services.
Treatment for cancer, HIV and viral hepatitis in Europe using low cost generic drugs: what could be done?
Andrew Hill, Chelsea and Westminster Hospital, London
One of the keynote lectures that was a conference highlight in showing the potential for medicines to be both cheaper and affordable in all settings. Also reported above in HTB.
Ending the HIV/AIDS pandemic: follow the science
Anthony Fauci, US NIAID/NIH), Bethesda
Keynote lecture in memory of Joep Lange and Jacqueline van Tongeren on the importance of building on scientific research to end global AIDS.